Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease

Experimental Neurology

Volumn 154, Issue 2, 1998, Pages 511-521

  Lidstrom A M ^a   Bogdanovic, N ^b   Hesse, C ^a   Volkman, I ^b   Davidsson, P ^a   Blennow, K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; ApoJ; Apolipoprotein J; Clusterin; Dementia; Immunohistochemistry; Inflammation; Regeneration

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CLUSTERIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACROGLIA; MALE; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SENILE PLAQUE;

EID: 0032411158     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6892     Document Type: Article

References (53)

1. Adolfsson R., Gottfries C. G., Nyström L., Winblad B. Prevalence of dementia in institutionalized Swedish old people: The work load imposed by caring for these patients. Acta Psychiat. Scand. 63:1981;225-244.
2. Alafuzoff I., Iqbal K., Fridén H., Adolfsson R., Winblad B. Histopathological criteria for progressive dementia disorders: Clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. (Berl.). 74:1987;209-225.
3. Bertrand P., Poirier J., Oda T., Finch C. E., Pasinetti G. M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease. Mol. Brain Res. 33:1995;174-178.
4. Blennow K., Bogdanovich N., Alafuzoff I., Ekman R., Davidsson P. Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J. Neural. Transm. (P-D Section). 103:1996;603-618.
5. Bogdanovic N., Morris J. C. Diagnostic criteria for Alzheimer's disease in multi-centre brain banking. Neuropathological Diagnostic Criteria for Brain Banking. 1995;IOS Press, Amsterdam. p. 20-29.
6. Boggs L. N., Fuson K. S., Baez M., Churgay L., McClure D., Becker G., May P. C. Clusterin (ApoJ) protects against in vitro amyloid-β(1-40) neurotoxicity. J. Neurochem. 67:1996;1324-1327.
7. Choi-Miura N. H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 83:1992;260-264.
8. Choi-Miura N. H., Oda T. Relationship between multifunctional protein "clusterin" and Alzheimer's disease. Neurobiol. Aging. 17:1996;717-722.
9. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
10. Danik M., Chabot J., Mercier C., Benabid A. L., Chauvin C., Quirion R., Suh M. Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc. Natl. Acad. Sci. USA. 88:1991;8577-8581.
11. de Silva H. V., Stuart W. D., Duvic C. R., Wetterau J. R., Ray M. J., Ferguson D. G., Albers W. H., Smith W. R., Harmony J. A. K. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem. 265:1990;13240-13247.
12. Dragunow M., Preston K., Dodd J., Young D., Lawlor P., Christie D. Clusterin accumulates in dying neurons following status epilepticus. Mol. Brain Res. 32:1995;279-290.
13. Duguid J. R., Bohmont C. W., Liu N., Tourtellotte W. W. Changes in brain gene expression shared by scrapie and Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 86:1989;7260-7264.
14. Eggertsen G., Tegelman R., Ericsson S., Angelin B., Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population: Variation of allele frequency with age and relation to serum lipid concentrations. Clin. Chem. 39:1993;2125-2129.
15. Eikelenboom P., Hack C. E., Rozemuller J. M., Stam F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 56:1989;259-262.
16. Eikelenboom P., Zhan S. S., van Gool W. A., Allsop D. Inflammatory mechanisms in Alzheimer's disease. TIPS. 15:1994;447-450.
17. Geddes J. W., Monaghan D. T., Cotman C. W., Lott I. T., Kim R. C., Chang Chui H. Plasticity of hippocampal circuitry in Alzheimer's disease. Science. 230:1985;1179-1181.
18. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293:1993;27-30.
19. Griffin W. S., Sheng J. G., Roberts G. W., Mrak R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
20. Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M., Binder L. I. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA. 83:1986;4913-4917.
21. Hamos J. E., DeGennaro L. J., Drachman D. A. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 39:1989;355-361.
22. Harr S. D., Uint L., Hollister R., Hyman B. T., Mendez A. J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J. Neurochem. 66:1996;2429-2435.
23. Hyman B. T., Kromer L. J., van Hoesen G. W. Reinnervation of the hippocampal perforant pathway zone in Alzheimer's disease. Ann. Neurol. 21:1987;259-267.
24. Jenne D. E., Tschopp J. Clusterin: The intriguing guises of a widely expressed glycoprotein. TIBS. 17:1992;154-159.
25. Johnson S. A., Lampert-Etchells M., Pasinetti G. M., Rozovsky I., Finch C. E. Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging. 13:1992;641-648.
26. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuter K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736.
27. Kida E., Choi-Miura N. H., Wisniewski K. E. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res. 685:1995;211-216.
28. Kida E., Pluta R., Lossinsky A. S., Golabek A. A., Choi-Miura N. H., Wisniewski H. M., Mossakowski M. J. Complete cerebral ischemia with short-term survival in rat induced by cardiac arrest. II. Extracellular and intracellular accumulation of apolipoprotein E and J in the brain. Brain Res. 674:1995;341-345.
29. Lampert-Etchells M., McNeill T. H., Laping N. J., Zarow C., Finch C. E., May P. C. Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning. Brain Res. 563:1991;101-106.
30. Landén M., Thorsell A., Wallin A., Blennow K. The apolipoprotein allele e4 does not correlate with the number of senile plaque or neurofibrillary tangles in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiat. 61:1996;352-356.
31. Laping N. J., Morgan T. E., Nichols N. R., Rozovsky I., Young-Chan C. S., Zarow C. E., Finch C. E. Transforming growth factor-β1 induces neuronal and astrocyte genes: tubulin α1, glial fibrillary acidic protein and clusterin. Neuroscience. 58:1994;563-572.
32. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82:1985;4245-4249.
33. Matsubara E., Soto C., Governale S., Frangione B., Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem. J. 316:1996;671-679.
34. May P. C., Johnson S. A., Poirier J., Lampert-Etchells M., Finch C. E. Altered gene expression in Alzheimer's disease brain tissue. Can. J. Neurol. Sci. 16:1989;473-476.
35. May P. C., Lampert-Etchells M., Johnson S. A., Poirier J., Masters J. N., Finch C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron. 5:1990;831-839.
36. McGeer P. L., Kawamata T., Walker D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579:1992;337-341.
37. Mullan M., Crawford F. Genetic and molecular advances in Alzheimer's disease. TINS. 16:1993;398-403.
38. Murphy B. F., Saunders J. R., O'Bryan M. K., Kirszbaum L., Walker I. D., d'Apice A. J. F. SP-40,40 is an inhibitor of C5b-6-initiated hemolysis. Int. Immunol. 1:1989;551-554.
39. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:1991;163-166.
40. O'Bryan M. K., Cheema S. S., Bartlett P. F., Murphy B. F., Pearse M. J. Clusterin levels increase during neuronal development. J. Neurobiol. 24:1992;421-432.
41. Oda T., Pasinetti G. M., Osterburg H. H., Anderson C., Johnson S. A., Finch C. E. Purification and characterization of brain clusterin. Biochem. Biophys. Res. Commun. 204:1994;1131-1136.
42. Pasinetti G. M., Finch C. E. Sulfated glycoprotein-2 (SGP-2) mRNA is expressed in rat striatal astrocytes following ibotenic acid lesions. Neurosci. Lett. 130:1991;1-4.
43. Pasinetti G. M., Johnson S. A., Oda T., Rozovsky I., Finch C. E. Clusterin (SGP-2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol. 339:1994;387-400.
44. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., Cotman C. W. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13:1993;1676-1687.
45. Poirier J., Davignon J., Bouthiller D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
46. Reddy K. B., Karode M. C., Harmony A. K., Howe P. H. Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin. Biochemistry. 35:1996;309-314.
47. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P., Lievervutg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 89:1992;10016-10020.
48. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimers disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
49. Tomlinson B. E., Corsellis J. A. N. Hume Adams J., Corsellis J. A. N., Duchen L. W. Greenfield's Neuropathology: 1984;951-1025 Edward Arnold, London.
50. van der Wal E. A., Gomez-Pinilla F., Cotman C. W. Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport. 4:1993;69-72.
51. Yamamoto T., Hirano A. A comparative study of modified Bielschowsky, Bodian and Thoiflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol. Appl. Neurobiol. 12:1986;3-9.
52. Zhan S. S., Veerhuis R., Kamphorst W., Eikelenboom P. Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration. 4:1995;291-297.
53. Zwain I. H., Grima J., Cheng C. Y. Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines. Mol. Cell. Neurosci. 5:1994;229-237.